New bipolar drug MK-8189 passes early safety check in small study

NCT ID NCT06273774

Completed Symptom relief Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested the safety of a drug called MK-8189 in 34 adults with stable bipolar I disorder. Researchers monitored side effects and how the drug moved through the body. The goal was to see if the drug is safe enough for further testing, not to measure how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar I disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR I DISORDER

Contacts and locations

Locations

Atlanta Center for Medical Research ( Site 0001)

Atlanta, Georgia, 30331, United States
Hassman Research Institute Marlton Site ( Site 0006)

Marlton, New Jersey, 08053, United States
Woodland International Research Group-Clinical Research ( Site 0009)

Little Rock, Arkansas, 72211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.